These findings indicate that CK2α contributes to the pathogenesis of colitis by promoting CD4+ T-cell proliferation and Th1 and Th17 cell responses (Figure 3), and that targeting CK2 may be a novel therapeutic treatment for patients with CD. Here, CD4 is linked to colitis.